FIELD: chemistry.
SUBSTANCE: invention relates to the novel compounds with formula I or their pharmaceutically acceptable salts and based on them pharmaceutics with the CRF (corticotrophin releasing factor) related activity. In the common formula I 
, X1 means (CH2)n, where n equal to 0-2, R1 means (1)C1-C10alkyl or C1-C10alkenyl, not necesserily substituted with substitute, selected from the group, including hydroxy, cyano, (C1-C3alkyl)arylamino and phenyl, and said phenyl not necesserily substituted with one-three substitutes, independently selected from the group including C1-C6alkyl, C1-C6alkoxi, halogen, (2) C3-C7cycloalkyl, not necesserily substituted with hydroxy,(3) C3-C7cycloalkyl(C1-C3)alkyl or C3-C7cycloalkenyl(C1-C3)alkyl,(4) C4-C12tricyclic alkyl,(5)C3-C7heterocycloalkyl or C3-C7heterocycloalkyl(C1-C3)alkyl, where each of the heterocyclic rings contains in the ring 1-2 heteroatoms, selected from nitrogen, oxygen or sulfur, and not necesserily can be substituted with the group C1-C3alkyl, phenyl or phenyl(C1-C6)alkyl, or the CH2 group in the heterocycloalkyl residue is substituted with C=O,(6) benzo-condensed (C5-C7)cycloalkyl,(7) phenyl, and said phenyl is not necesserily substituted with one-three substitutes, independently selected from the group including C1-C6alkyl, C1-C6alkoxi, methylendioxy, halogen, (8) naftyl, (9) heteroaryl(C1-C6)alkyl, and said heteroaryl(C1-C6)alkyl has 5-6 atoms in the ring and contains 1-2 heteroatoms, selected from nitrogen, oxygen or sulfur, can be condensed with the benzene ring and not necesserily substituted with one-three substitutes, selected from the group, including C1-C6alkyl, (10) 1,2-diphenylethyl,(12) C1-C3alkoxi(C1-C6)alkyl or (13) aryloxy(C1-C6)alkyl, R2 means C1-C6alkyl, R3 means (1) hydrogen,(2) C1-C6alkyl, not necesserily substituted with the group C1-C3acyloxy,(3) C3-C6alkenyl,(8) benzene, and R4 means phenyl, not necesserily substituted with one-three substitutes, independently selected from the group including C1-C6alkyl, halogen.
EFFECT: compounds can be used in treatment of phobias, stress dependent disorders, mental disorders, gastro-intestine disfunctions, neurodegenerative and other psychoneurologic disease.
19 cl, 2 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2020 |
|
RU2780101C2 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2021 |
|
RU2780103C1 |
| DERIVATIVES OF PYRAZIOLE WITH CONDENSED CYCLE | 2002 |
|
RU2318822C2 |
| INDAZOL DERIVATIVES AS CRF ANTAGONISTS | 2003 |
|
RU2341518C2 |
| Axl INHIBITORS APPLICABLE IN COMBINATION THERAPY FOR PREVENTING, RELIEVING OR TREATING METASTATIC CANCER | 2010 |
|
RU2555326C2 |
| CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS | 1995 |
|
RU2221799C2 |
| HETEROCYCLIC TGR5 BILE ACID RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR PREPARING AND USING THEM | 2013 |
|
RU2543485C2 |
| BICYCLIC PYRIDINES AND ANALOGUES AS SIRTUIN MODULATORS | 2010 |
|
RU2550821C2 |
| PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
| ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYLAMINES AND THEIR USING AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2301797C2 |
